Skip to main content
. 2022 Apr 21;2022:8133505. doi: 10.1155/2022/8133505

Figure 1.

Figure 1

Upregulated CISD2 expression predicts dismal outcomes in patients with glioma. (a) The protein levels of CISD2 in glioma from the HPA database. Brown (black) arrows reveal CISD2-positive staining. (b) CISD2 mRNA expression in glioma and normal tissues. (c–i) CISD2 mRNA expression in various subgroups, including (c) age, (d) sex, (e) histologic grade, (f) histological type, (g) IDH status, (h) 1p/19q codeletion status, and (i) primary therapy outcome. (j) Receiver operating characteristic curve analysis of tissue CISD2 expression to detect patients with glioma. ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001.